Acoramidis: A New Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy
Annals of PharmacotherapyObjective: The objective of the study was to review acoramidis, a new transthyretin stabilizer, for treatment of transthyretin amyloid cardiomyopathy by means of pharmacology, efficacy, and safety. Data sources: An Embase, PubMed, and ...
Taylor Clark +4 more
openaire +2 more sources
Vutrisiran (Amvuttra) for Transthyretin Amyloid Cardiomyopathy
The Medical Letter on Drugs and TherapeuticsThe FDA has approved vutrisiran (Amvuttra – Alnylam), a subcutaneously injected small interfering RNA (siRNA), to reduce cardiovascular hospitalizations, urgent heart failure visits, and cardiovascular death in adults with wild-type or variant transthyretin amyloid cardiomyopathy (ATTR-CM).
openaire +2 more sources
Transthyretin Amyloid Cardiomyopathy: A Review of Approved Pharmacotherapies
Cardiology in ReviewTransthyretin (TTR) amyloidosis (ATTR) occurs due to misfolding and aggregation of TTR protein in numerous organs and tissues, resulting in various clinical presentations including cardiomyopathy and polyneuropathy. The pathophysiology of ATTR cardiomyopathy is characterized by TTR deposition in the interstitial space between cardiac myocytes ...
Mohammed, Kallash, William H, Frishman
openaire +2 more sources
Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy
Progress in Cardiovascular DiseasesTransthyretin amyloid cardiomyopathy (ATTR-CM) is an underrecognized cause of heart failure (HF). ATTR-CM can lead to a number of cardiovascular manifestations including HF, rhythm disturbances, and valvular disease that ultimately limit quality of life and prognosis.
Joban, Vaishnav +2 more
openaire +2 more sources
Transthyretin Amyloid Cardiomyopathy as the Cause of Aortic Stenosis
KardiologiiaCurrently, the diagnosis of amyloid cardiomyopathy (ACM) causes great difficulties both for practicing primary care physicians and specialists. One of the reasons is the variety of symptoms in patients with ACM. The most common ACM manifestations include heart failure with preserved left ventricular ejection fraction, hypertrophic phenotype of ...
M. V. Ezhikova +8 more
openaire +2 more sources
Bio-Profiling of Transthyretin Amyloid Cardiomyopathy
JACC: Heart Failure, 2021openaire +2 more sources
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy
JACC: Heart Failure, 2021Mathew S Maurer, Kurt Boman, John L Berk
exaly
Transthyretin Amyloid Cardiomyopathy—Current and Future Therapies
Annals of Pharmacotherapy, 2021Jankhna D Yadav, Paul P Belliveau
exaly
Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy
Annals of Pharmacotherapy, 2020Hua Ling
exaly
Beta-Blocker Exposure and Survival in Patients With Transthyretin Amyloid Cardiomyopathy
Mayo Clinic Proceedings, 2022Eduardo Barge-Caballero +2 more
exaly